OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Additional Paid In Capital
OSE Immunotherapeutics SA
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Additional Paid In Capital
€76.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Additional Paid In Capital
€647.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Innate Pharma SA
PAR:IPH
|
Additional Paid In Capital
€391m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Additional Paid In Capital
€446.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Additional Paid In Capital
€201.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Additional Paid In Capital
€20.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-16%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Additional Paid In Capital?
Additional Paid In Capital
76.8m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Additional Paid In Capital amounts to 76.8m EUR.
What is OSE Immunotherapeutics SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
10%
Over the last year, the Additional Paid In Capital growth was 16%. The average annual Additional Paid In Capital growth rates for OSE Immunotherapeutics SA have been 5% over the past three years , 10% over the past five years .
You don't have any saved screeners yet